Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ramucirumab beyond progression plus TAS-102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab-based therapy.
Goetze TO, Stein A, Lorenzen S, Habibzada T, Goekkurt E, Herhaus P, Loose M, Sookthai D, Brulin T, Ihrig K, Pauligk C, Al-Batran SE. Goetze TO, et al. Among authors: pauligk c. Int J Cancer. 2023 Nov 15;153(10):1726-1733. doi: 10.1002/ijc.34652. Epub 2023 Jul 16. Int J Cancer. 2023. PMID: 37455496
Imatinib mesylate for targeting the platelet-derived growth factor beta receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer--a dose-escalation Phase I trial.
Al-Batran SE, Atmaca A, Schleyer E, Pauligk C, Hosius C, Ehninger G, Jäger E. Al-Batran SE, et al. Among authors: pauligk c. Cancer. 2007 May 1;109(9):1897-904. doi: 10.1002/cncr.22622. Cancer. 2007. PMID: 17377918 Free article. Clinical Trial.
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jäger E; Arbeitsgemeinschaft Internistische Onkologie. Al-Batran SE, et al. Among authors: pauligk c. J Clin Oncol. 2008 Mar 20;26(9):1435-42. doi: 10.1200/JCO.2007.13.9378. J Clin Oncol. 2008. PMID: 18349393 Clinical Trial.
The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+).
Al-Batran SE, Pauligk C, Homann N, Hartmann JT, Moehler M, Probst S, Rethwisch V, Stoehlmacher-Williams J, Prasnikar N, Hollerbach S, Bokemeyer C, Mahlberg R, Hofheinz RD, Luley K, Kullmann F, Jäger E. Al-Batran SE, et al. Among authors: pauligk c. Eur J Cancer. 2013 Mar;49(4):835-42. doi: 10.1016/j.ejca.2012.09.025. Epub 2012 Oct 11. Eur J Cancer. 2013. PMID: 23063354 Clinical Trial.
Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer.
Lorenzen S, Pauligk C, Homann N, Schmalenberg H, Jäger E, Al-Batran SE. Lorenzen S, et al. Among authors: pauligk c. Br J Cancer. 2013 Feb 19;108(3):519-26. doi: 10.1038/bjc.2012.588. Epub 2013 Jan 15. Br J Cancer. 2013. PMID: 23322206 Free PMC article. Clinical Trial.
A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer.
Atmaca A, Al-Batran SE, Werner D, Pauligk C, Güner T, Koepke A, Bernhard H, Wenzel T, Banat AG, Brueck P, Caca K, Prasnikar N, Kullmann F, Günther Derigs H, Koenigsmann M, Dingeldein G, Neuhaus T, Jäger E. Atmaca A, et al. Among authors: pauligk c. Br J Cancer. 2013 Feb 5;108(2):265-70. doi: 10.1038/bjc.2012.555. Epub 2013 Jan 17. Br J Cancer. 2013. PMID: 23329236 Free PMC article. Clinical Trial.
51 results